



The 135th Central Research Laboratory Seminar

Therapeutic anti-amyloid antibodies in Alzheimer's disease. Unveiling promise and challenges.

Dr. Jean-Pierre Bellier

Staff scientist

Department of Neurology

Brigham and Women's Hospital, Harvard University

Date January 30 (Tue), 2024, 17:30~18:30

Venue Clinical Lecture Room 1
***Also delivered online via Zoom**

Recent successful trials with monoclonal therapeutic antibodies targeting amyloid-beta have not only shown improvements in markers of Alzheimer's disease (AD) pathology but also demonstrated potential in modifying the course of AD-related cognitive decline. While this treatment holds significant promise, it raises new questions, some with direct clinical implications like the drug bioavailability and the origin of Amyloid-Related Imaging Abnormalities (ARIA), while others are more theoretical, such as isolating the molecular determinants of antibody-antigen interaction and understanding the mechanism for amyloid beta plaque removal. Addressing these questions could significantly enhance the safety and efficiency of therapeutic antibodies against AD.

**This is a formal seminar in part of Basic Science
Fundamentals and Multidisciplinary Seminars.**



Okunosu, a small island in Lake Biwa